PSA Density Calculator

What is PSA density and why does it matter?

Prostate-specific antigen (PSA) is a protein produced by prostate cells, and some of it enters the bloodstream where it can be measured. Both cancerous and non-cancerous prostate tissue produce PSA, so a raised PSA does not automatically mean cancer: a larger prostate simply makes more PSA even when perfectly benign. PSA density (PSAD) corrects for this by dividing the serum PSA by the prostate volume. A man with a serum PSA of 6 ng/mL and a 70 mL prostate has a PSAD of 0.086, which is reassuringly low. The same PSA in a man with a 25 mL prostate gives a PSAD of 0.24, which is more concerning, because that smaller gland should not be producing that much PSA. PSAD therefore helps clinicians separate the signal (cancer) from the noise (benign enlargement), reducing unnecessary biopsies while still identifying men who genuinely need further investigation.

How prostate volume is estimated from imaging

Radiologists measure three perpendicular diameters of the prostate on ultrasound or MRI: the anteroposterior (AP, front-to-back) length, the transverse (left-to-right) width, and the craniocaudal (head-to-toe) height. The standard ellipsoid formula multiplies these three dimensions by 0.52 (which equals pi/6, the same constant used to estimate the volume of a perfect ellipsoid). This method is accurate for the typical oval-shaped prostate. For smaller or more spherical glands, some radiologists prefer the bullet formula, which uses a constant of 0.65 and tends to give a slightly larger volume estimate. Using the right formula matters because the volume goes directly into the PSAD denominator: a 25 percent difference in the constant changes the PSAD by 25 percent in the other direction. Always confirm which formula your radiology report used before comparing results.

How to interpret your PSAD result

The most widely cited threshold is 0.15 ng/mL/mL: values at or above this level are associated with a meaningfully higher probability of clinically significant prostate cancer, and most major urology guidelines use this cut-off when deciding whether to recommend biopsy in men with an otherwise equivocal PSA result. The EAU guideline groups PSA density into four bands - below 0.10 (low), 0.10 to 0.15 (intermediate-low), 0.15 to 0.20 (intermediate-high), and above 0.20 (high) - and pairs each band with the MRI PI-RADS score to decide whether biopsy is needed. A PSAD below 0.10 is generally considered reassuring, particularly when a multiparametric MRI of the prostate is also negative (PI-RADS 1 or 2). The zone between 0.10 and 0.15 is typically managed by combining PSAD with other information: PSA velocity (how fast PSA is rising), the free-to-total PSA ratio, MRI findings, and individual risk factors such as family history or African ancestry. Note that these bands are not adjusted for age. Age-specific reference ranges exist for total PSA, but current guidelines do not publish age-specific PSA density cut-offs, and studies that have looked for them concluded they add little clinical value.

PSAD limitations and what else to consider

PSAD improves on raw PSA, but it is not a definitive diagnostic test. Prostate volume estimates vary by imaging modality, operator technique, and the formula used. Measurement errors of even a few millimetres can shift the volume by 10-20 percent, which changes the PSAD accordingly. Certain medicines such as 5-alpha-reductase inhibitors (finasteride, dutasteride) suppress PSA by roughly half, so the measured PSA should be doubled before calculating PSAD if you take them. The transition-zone PSA density (PSA divided by the inner gland volume alone) has been shown in some studies to discriminate better than whole-gland PSAD, though it is less commonly used in routine practice. PSAD is best interpreted alongside a complete clinical picture: digital rectal examination findings, PSA kinetics, MRI PI-RADS category, patient age, and shared-decision discussions with a urologist.